13F-HR filed by Cutter Capital Management, LP
Cutter Capital Management, LP filed this 13F-HR for the quarter ended 2023-12-31, filed 2024-02-14, with 23 holding rows worth $209,169,979.
- Accession
- 0001214659-24-002814
- Filer
- CIK 1983313
- Filed
- 2024-02-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2023
A holdings report, 23 entries on the cover page, a total value of $209,169,979 stated on the cover page (in dollars after the unit check, H1), rows summing to $209,169,979 with VALUE read as dollars as filed, 13F file number 028-23904. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| Amgen Inc. | 031162100 | COM | 57,381 | $16,526,876 | dollars as filed | |
| Merck & Co.,Inc. | 58933Y105 | COM | 136,098 | $14,837,404 | dollars as filed | |
| AMICUS THERAPEUTICS INC | 03152W109 | COM | 947,418 | $13,443,861 | dollars as filed | |
| INSMED INC COM PAR $.01 | 457669307 | Stock | 413,499 | $12,814,334 | dollars as filed | |
| BIOMARIN PHARMACEUTICAL INC | 09061G101 | COM | 129,906 | $12,525,537 | dollars as filed | |
| ROIVANT SCIENCES LTD | G76279101 | SHS | 1,000,000 | $11,230,000 | dollars as filed | |
| EXELIXIS INC COM | 30161Q104 | Stock | 462,305 | $11,090,697 | dollars as filed | |
| TEVA PHARMACEUTICAL INDS LTD SPONSORED ADS | 881624209 | ADR | 1,061,668 | $11,083,814 | dollars as filed | |
| ROYALTY PHARMA PLC | G7709Q104 | SHS CLASS A | 370,000 | $10,393,300 | dollars as filed | |
| ACADIA PHARMACEUTICALS INC | 004225108 | COM | 330,973 | $10,362,765 | dollars as filed | |
| BIOCRYST PHARMACEUTICALS INC COM | 09058V103 | Stock | 1,521,812 | $9,115,654 | dollars as filed | |
| HALOZYME THERAPEUTICS INC COM | 40637H109 | Stock | 240,448 | $8,886,958 | dollars as filed | |
| PERRIGO CO PLC SHS | G97822103 | Stock | 260,000 | $8,366,800 | dollars as filed | |
| Pfizer Inc. | 717081103 | COM | 265,000 | $7,629,350 | dollars as filed | |
| Bristol-Myers Squibb Company | 110122108 | COM | 140,000 | $7,183,400 | dollars as filed | |
| CRISPR THERAPEUTICS AG NAMEN AKT | H17182108 | Stock | 107,500 | $6,729,500 | dollars as filed | |
| VIRIDIAN THERAPEUTICS INC | 92790C104 | COM | 307,721 | $6,702,163 | dollars as filed | |
| APELLIS PHARMACEUTICALS INC | 03753U106 | COM | 108,000 | $6,464,880 | dollars as filed | |
| IOVANCE BIOTHERAPEUTICS INC | 462260100 | COM | 677,350 | $5,506,856 | dollars as filed | |
| CABALETTA BIO INC | 12674W109 | COMMON STOCK | 230,000 | $5,221,000 | dollars as filed | |
| PRESTIGE CONSMR HEALTHCARE I | 74112D101 | COM | 85,000 | $5,203,700 | dollars as filed | |
| BRIDGEBIO PHARMA INC | 10806X102 | COM | 103,324 | $4,171,190 | dollars as filed | |
| ARCUS BIOSCIENCES INC | 03969F109 | COM | 192,667 | $3,679,940 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001214659-24-002814 | this filing | 2024-02-14 | acceptance time not in the bulk data set |